Dr. Neelapu on Emerging CAR T-Cell Therapies in Relapsed/Refractory MCL


Sattva Neelapu, MD, discusses emerging CAR T-cell therapies for patients with relapsed/refractory mantle cell lymphoma.

Sattva Neelapu, MD, a professor of Lymphoma and Myeloma at The University of Texas MD Anderson Cancer Center, discusses emerging CAR T-cell therapies for patients with relapsed/refractory mantle cell lymphoma (MCL).

Brexucabtagene autoleucel (brexu-cel; Tecartus) was approved by the FDA in July 2020 for relapsed/refractory MCL, and shares many similarities with axicabtagene ciloleucel (axi-cel; Yescarta), which was approved by the FDA for use in adult patients with relapsed or refractory large B-cell lymphoma in October 2017, Neelapu says; the main difference between the products has to do with how they are manufactured.

In the multicenter phase 2 ZUMA-2 trial (NCT02601313), patients who received brexu-cel achieved a complete response (CR) rate of 67%, Neelapu notes. At a median follow-up of about 18 months, 48% of patients continued to respond to the product, according to data presented at the 2020 ASH Annual Meeting & Exposition.

Another product that is currently under review for patients with MCL if lisocabtagene maraleucel (liso-cel; Breyanzi), which is being examined in the phase 1 TRANSCEND NHL 001 trial (NCT02631044). An interim analysis presented at the 2020 ASH Meeting and Exposition examined outcomes with the agent in 32 patients. In total, 66% of patients achieved a CR, though a longer follow-up is needed in order to confirm the agent's benefit, Neelapu concludes.

Related Videos
Sowmya Viswanathan, PhD, on Translating Cell Therapies to the Clinic at ISCT 2024
Omar Nadeem, MD, on Initial Efficacy of GPRC5D-CAR in R/R Multiple Myeloma
Omer A. Abdul Hamid, MD, on Improving Gene Therapy’s Effect and Accessibility
George Tachas, PhD, on Tackling DMD Treatment From Multiple Angles
David Suhy, PhD, the cofounder and chief scientific officer of Earli
Deepak L. Bhatt, MD, MPH, MBA, on Incorporating AI into Genetic Research for Cardiovascular Disease
Jeffrey Chamberlain, PhD, on Helping Progress Cell and Gene Therapy Development
Jonathan W. Weinsaft, MD, on Integrating Genetic Research into Cardiovascular Medicine
Jacques Galipeau, MD, on Highlights from ISCT 2024’s Presidential Plenary
Vanee Pho, PhD, the senior director of product management, cell and gene therapy, at Mission Bio
© 2024 MJH Life Sciences

All rights reserved.